Australian cell therapy company Chimeric Therapeutics (ASX:CHM) has strengthened its leadership, appointing experienced biotechnology executive Dr Bradley Glover as Non-Executive Director and Chair, and naming a new Chief Financial Officer, as part of a broader governance refresh.
The changes follow a board renewal process first announced in November 2025, during which the company undertook a global search that reviewed more than 30 potential chair candidates. After presentations to the independent Non-Executive Directors, Dr Glover emerged as the preferred choice and has assumed the role effective immediately.
Dr Glover brings more than two decades of experience across the global biopharmaceutical and life sciences sectors, spanning cell and gene therapy, biomaterials, and broader biotechnology innovation in both public and private markets. His background combines scientific depth with commercial execution, particularly in advancing advanced therapies through clinical development, manufacturing scale-up and market launch.
Over his career, Dr Glover has helped drive autologous and allogeneic CAR-T and NK cell therapy programs across both blood cancers and solid tumours, supporting products from early research stages through to commercialisation. He has held senior leadership roles at Imugene, Celularity, Kite Pharma, Genentech, Roche and Illumina, where his responsibilities included corporate strategy, business development, supply chain expansion and launch execution. Notably, he contributed to the commercial launches of major cell therapies YESCARTA and TECARTUS.
Dr Glover also brings experience in capital formation and strategic transactions, working closely with boards and investors to navigate key inflection points in company growth. He also currently serves on the boards of Lamorinda Therapeutics and Basilard BioTech. His academic credentials include a biochemistry degree from the University of California, San Diego, a PhD in biochemistry and molecular genetics from the University of Colorado, and an MBA from UCSD’s Rady School of Management. He was also a Jane Coffin Childs Medical Research Fellow at the University of California, Berkeley.
Acting Chair Phillip Hains said the appointment comes at an important stage in Chimeric’s evolution. He noted that Dr Glover’s experience in cell therapy development and his international pharmaceutical networks would complement the company’s existing leadership team and support its next phase of growth.
Mr Hains will remain on the board as a Non-Executive Director for a transition period but will step down from his executive responsibilities as Joint Company Secretary and Chief Financial Officer on 16 February 2026.
To fill the finance role, Chimeric has appointed Aaron Laurita as Chief Financial Officer, effective immediately. Mr Laurita brings a decade of finance and commercial experience across multiple industries, including biotechnology, with work spanning Australia, the United States and Canada. He holds a Bachelor of Business in Professional Accountancy from RMIT University and is a Chartered Accountant and member of Chartered Accountants Australia and New Zealand.